During the three months ended March 31, 2021, the company spent $98 million on capital expenditures as compared to $61 million in the same period of 2020
With no significant planned maintenance for our assets during the second quarter, we plan to operate at nearly full capacity worldwide to meet robust demand
The company posted net profit of Rs.175.05 crores for the period ended March 31, 2021
WACKER performed very well in Q1 2021
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
Completed a planned turnaround at the Geismar 2 plant and expects to complete the Geismar 2 debottlenecking project by mid-2021.
Acquisition will enable accelerated growth of key animal nutrition markets
Sales revenue from chemical intermediates increased 2% driven by a 14% increase in selling prices
EBITDA of CHF 164 million rose by 4 % in Swiss francs, generating a notably improved EBITDA margin at 16.4 % (vs. 15.4 %)
For every 100 kg of LNP compound, 21 kg of fossil-based materials have been replaced with bio-based materials
The company has achieved robust EBITDA growth of 21%, the EBITDA for the quarter stood at Rs. 195 crores as compared to Rs. 161 crores in the corresponding quarter last year
The company has scored 68 out of 100 which places the company in the top 5% of all companies assessed under the worldwide rating system
Dr. Reddy’s Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two
UHPCs has been verified by the association of German cement manufacturers (VDZ) based on an analysis of compressive strength conducted to DIN EN 12390-3
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
For supplying life sciences related specialty chemicals
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Partnership with Cheminox to include Bangladesh, Nepal and Sri Lanka, effective April 1st, 2021.
A 400 beds Covid Care facility will be up and running at Government Dental College & Hospital in Jamnagar
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Subscribe To Our Newsletter & Stay Updated
